This Drugmaker Will Survive Its 'Patent Cliff'
Dr. David EifrigRetirement Trader
Wednesday, November 23rd, 2022 at 5:49 PM
In today's issue of Retirement Trader, editor Dr. David Eifrig recommends a company that's a perfect opportunity to sell options. Investors have priced in a likely revenue loss, but we're optimistic about its future...